| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 39
| Issue : 2 | Page : 52-57 |
|
|
High levels of soluble thrombomodulin may be a marker of arterial disease and peripheral ischemia in Egyptian patients with diabetes mellitus
Walaa A Elsalakawy1, Botheina A.T. Farweez2, Mohamed T.H. Sallam2, Mohamed A Hamza3
1 Department of Internal Medicine, Clinical Hematology and Bone Marrow Transplant Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3 Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Correspondence Address:
Walaa A Elsalakawy
Clinical Hematology and Bone Marrow Transplant Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Block 9, Building 1, Apart. 303,
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1110-1067.139759
|
|
|
Background Thrombomodulin is an endothelial cell membrane protein acting as a cofactor for the activation of plasma protein C. It was found that soluble forms of thrombomodulin (sTM) exist in plasma and is considered a marker of endothelial dysfunction.
Materials and methods The study included 160 individuals: 40 healthy controls and 120 diabetic patients (40 patients with type 1 diabetes and 80 patients with type 2 diabetes). sTM concentrations were measured by an enzyme-linked immunosorbent assay-based assay employing monoclonal antithrombomodulin antibodies.
Results The diabetic patients had highly significantly increased plasma sTM concentrations compared with the control group (P < 0.001). Type 2 diabetic patients with peripheral limb ischemia showed a highly significant increase in plasma sTM levels when compared with type 2 or type 1 diabetic patients without ischemia (P < 0.001). sTM concentrations were positively correlated with age, duration of diabetes, and urinary albumin concentration, with highly significant P value (P < 0.001). A cutoff value of greater than 9500 ng/ml of sTM was found to be of 96.9% diagnostic accuracy in differentiating type 2 diabetic patients with and without peripheral limb ischemia.
Conclusion We recommend including sTM in the follow-up panel of diabetic patients because of its potential ability to predict the risk for ischemic manifestations.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
